May 2, 2023 07:06 AM EDTUpdated 10:44 AM
Deals
Bioregnum

J&J goes block­buster hunt­ing (again) with $245M cash up­front for next-gen CAR-T

J&J is work­ing on cre­at­ing its next Leg­end. On­ly this time, it’s mov­ing right in­to the dri­ver’s seat in­stead of tak­ing the co-pi­lot role. …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times